ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
Dow Jones
38,239.66
0.40%
US Dollar vs MXN
17.1601
0.00%
Brent Oil
88.165
0.00%
Bitcoin
63,059.00
-1.07%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. XORTX Therapeutics Inc (XRTX)

  7. XORTX Therapeutics Inc (XRTX) Noticias

XRTX XORTX Therapeutics Inc

2.93
0.34 (13.13%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
XORTX Therapeutics Inc XRTX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.34 13.13% 2.93 15:59:59
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.75 2.5301 3.00 2.93 2.59
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
22/4/202406:00GLOBEXORTX Announces Publication of Key Research in ADPKD
08/4/202406:30GLOBEXORTX Welcomes New Member to the Board of Directors
08/4/202406:00GLOBEXORTX Announces Participation in Spring 2024 Investor..
27/3/202404:00GLOBEXORTX Announces New Clinical Advisory Board Member
19/3/202404:00GLOBEXORTX Highlights Achievements of 2023 and Preparation for..
11/3/202406:00GLOBEXORTX Reprices Warrants Issued in Connection with Previous..
04/3/202406:00GLOBEXORTX Finalizes $2.7 Million Prospectus Supplement and..
15/2/202406:00GLOBEXORTX Raises $2.5 Million Under Prospectus Supplement and..
01/2/202419:46GLOBEXORTX Files an Amended and Restated Prospectus Supplement..
15/1/202406:00GLOBEXORTX Announces $2 Million Public Offering
03/1/202406:25EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/1/202406:00GLOBEXORTX Submits a New Patent for the Treatment of Chronic..
02/1/202407:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/1/202406:00GLOBEXORTX Welcomes New Member to the Board of Directors
30/11/202315:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/11/202306:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/11/202306:30GLOBEXORTX Announces US ATM Offering
29/11/202320:57EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/11/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/11/202306:00GLOBEXORTX Meets Nasdaq Continued Listing Requirements
13/11/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/11/202306:00GLOBEXORTX Clarifies Timing for Share Consolidation
08/11/202316:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/11/202316:00GLOBEXORTX Announces Share Consolidation
02/11/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/11/202306:00GLOBEXORTX Sponsored Study Presented at the American Society of..
27/10/202316:30GLOBEXORTX Announces Results of Special Meeting of Shareholders
25/10/202316:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/10/202316:00GLOBEXORTX Announces Date for Rescheduled Special Meeting of..
25/10/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/10/202306:00GLOBEXORTX Announces Rescheduling of Special Meeting of..
12/10/202306:41EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/10/202306:00GLOBEXORTX Reports that Independent Proxy Firm, ISS, Recommends..
04/10/202312:11EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/10/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/10/202306:00GLOBEXORTX Calls Special Meeting of Shareholders
28/9/202306:56EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/9/202306:00GLOBEXORTX Sponsored Study Selected for Presentation at the..
12/9/202314:56EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/9/202306:00GLOBEXORTX Announces Participation at Upcoming Investor..
07/9/202307:23EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/9/202306:00GLOBEXORTX Joins the Kidney Foundation and Kidney March
29/8/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/8/202306:00GLOBEXORTX Submits Orphan Drug Designation Application to the..
25/8/202305:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/8/202315:42EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/8/202315:40EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
07/8/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
04/8/202316:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/8/202316:00GLOBEXORTX Appoints Chief Financial Officer

Su Consulta Reciente

NASDAQ
XRTX
XORTX Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados